FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application from BluePoint Laboratories for levetiracetam, authorizing approval of a generic version of the anti-seizure medication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Generalized Tonic-clonic Seizures
• Juvenile Myoclonic Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Keppra (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)